Quick Answer
Rani Therapeutics Holdings, Inc. reported Operating Income Loss of -$38.31 million for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +28.1% in Operating Income Loss from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$3.39 million | Q3 2020: -$2.83 million | Q1 2021: -$5.20 million | Q2 2021: -$5.26 million | Q3 2021: -$27.78 million | Q1 2022: -$13.78 million | Q2 2022: -$15.85 million | Q3 2022: -$16.34 million | Q1 2023: -$16.52 million | Q2 2023: -$18.29 million | Q3 2023: -$17.86 million | Q1 2024: -$14.03 million | Q2 2024: -$12.52 million | Q3 2024: -$11.80 million | Q1 2025: -$12.01 million | Q2 2025: -$10.51 million | Q3 2025: -$7.26 million.
- Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Operating Income Loss has declined by 131.6%.
- Historical annual values: Fiscal year 2025: -$38.31 million | Fiscal year 2024: -$53.31 million | Fiscal year 2023: -$66.10 million | Fiscal year 2022: -$63.45 million | Fiscal year 2021: -$51.60 million | Fiscal year 2020: -$16.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: